Sectoral Asset Management Lowered By $19.04 Million Its Acceleron Pharma (XLRN) Position; RICOH CO LTD ORDINARY SHARES (RICOF) Sellers Decreased By 4.89% Their Shorts

June 10, 2018 - By Nellie Frank

Ricoh Company, Ltd. (OTCMKTS:RICOF) Logo

RICOH CO LTD ORDINARY SHARES (OTCMKTS:RICOF) had a decrease of 4.89% in short interest. RICOF’s SI was 3.16 million shares in June as released by FINRA. Its down 4.89% from 3.32M shares previously. With 400 avg volume, 7903 days are for RICOH CO LTD ORDINARY SHARES (OTCMKTS:RICOF)’s short sellers to cover RICOF’s short positions. It closed at $11.04 lastly. It is down 0.00% since June 10, 2017 and is . It has underperformed by 12.57% the S&P500.

Sectoral Asset Management Inc decreased Acceleron Pharma (XLRN) stake by 68.52% reported in 2018Q1 SEC filing. Sectoral Asset Management Inc sold 488,130 shares as Acceleron Pharma (XLRN)’s stock declined 18.55%. The Sectoral Asset Management Inc holds 224,226 shares with $8.77M value, down from 712,356 last quarter. Acceleron Pharma now has $1.65 billion valuation. The stock increased 0.47% or $0.17 during the last trading session, reaching $36.02. About 411,152 shares traded or 36.39% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.77% since June 10, 2017 and is uptrending. It has outperformed by 25.20% the S&P500. Some Historical XLRN News: ; 01/05/2018 – ACCELERON GETS FDA FAST TRACK FOR ACE-083 IN FSHD; 02/05/2018 – Acceleron Presenting at UBS Conference May 22; 08/05/2018 – ACCELERON 1Q LOSS/SHR 58C, EST. LOSS/SHR 65C; 02/05/2018 – Acceleron to Participate in Two Healthcare Investor Conferences in May; 08/05/2018 – ACCELERON PHARMA – BELIEVES EXISTING CASH, CASH EQUIVALENTS & INVESTMENTS TO BE SUFFICIENT TO FUND PROJECTED OPERATING REQUIREMENTS INTO 2021; 26/04/2018 – Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting; 07/05/2018 – Acceleron at Deutsche Bank Health Care Conference Tomorrow; 30/04/2018 – Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018; 19/03/2018 – CAFC: DELL INC. v. ACCELERON, LLC [OPINION] – Appeal #17-1101 – 2018-03-19; 19/04/2018 – DJ Acceleron Pharma Inc, Inst Holders, 1Q 2018 (XLRN)

Investors sentiment increased to 1.27 in 2018 Q1. Its up 0.18, from 1.09 in 2017Q4. It increased, as 13 investors sold XLRN shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported. 57,195 were accumulated by Commercial Bank Of America De. Waddell Reed holds 0% or 28,300 shares in its portfolio. Sectoral Asset Mngmt holds 224,226 shares or 0.96% of its portfolio. New York State Common Retirement Fund reported 0.01% stake. California State Teachers Retirement Systems has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Citadel Advisors Limited Liability Com owns 160,515 shares. Citigroup owns 38,809 shares or 0% of their US portfolio. Goldman Sachs Group holds 555,019 shares or 0.01% of its portfolio. Price T Rowe Associates Inc Md stated it has 3.63M shares or 0.02% of all its holdings. Proshare Advsr Ltd Liability Company reported 25,799 shares or 0.01% of all its holdings. Dekabank Deutsche Girozentrale has invested 0.08% in Acceleron Pharma Inc. (NASDAQ:XLRN). 5,611 are held by Invesco Limited. Td Asset Management Inc accumulated 72,700 shares or 0% of the stock. Birchview Limited Partnership invested in 25,000 shares or 0.64% of the stock. 9,478 were accumulated by Raymond James & Assoc.

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 12 have Buy rating, 1 Sell and 3 Hold. Therefore 75% are positive. Acceleron Pharma had 41 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was reinitiated by Oppenheimer with “Outperform” on Monday, February 1. The company was maintained on Thursday, March 1 by Citigroup. On Friday, June 23 the stock rating was maintained by FBR Capital with “Buy”. The rating was initiated by Oppenheimer on Friday, November 20 with “Outperform”. The firm earned “Hold” rating on Tuesday, May 22 by Oppenheimer. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, February 28 report. Citigroup upgraded Acceleron Pharma Inc. (NASDAQ:XLRN) on Thursday, March 2 to “Buy” rating. Citigroup initiated Acceleron Pharma Inc. (NASDAQ:XLRN) on Thursday, September 29 with “Neutral” rating. H.C. Wainwright initiated Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Monday, January 8. H.C. Wainwright has “Buy” rating and $62.0 target. The rating was maintained by Barclays Capital with “Overweight” on Monday, June 13.

Sectoral Asset Management Inc increased Medtronic Plc (NYSE:MDT) stake by 42,990 shares to 224,600 valued at $18.02 million in 2018Q1. It also upped Johnson & Johnson (NYSE:JNJ) stake by 6,599 shares and now owns 220,948 shares. La Jolla Pharmaceutical (NASDAQ:LJPC) was raised too.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on August, 2. They expect $-0.64 EPS, up 16.88% or $0.13 from last year’s $-0.77 per share. After $-0.58 actual EPS reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts 10.34% negative EPS growth.

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: which released: “Acceleron: Luspatercept New Data Is A Buy Signal” on June 07, 2018, also with their article: “Big News Is Fast Approaching for Celgene” published on June 08, 2018, published: “Acceleron Pharma’s (XLRN) CEO Habib Dable on Q1 2018 Results – Earnings Call Transcript” on May 14, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: and their article: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” published on June 03, 2018 as well as‘s news article titled: “SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion” with publication date: May 21, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts